Cargando…

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922

Oncogenic mutations of BRAF occur in approximately 10% of colon cancers and are associated with their resistance to clinically available therapeutic drugs and poor prognosis of the patients. Here we report that colon cancer cells with mutant BRAF are also resistant to the heat shock protein 90 (HSP9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chun Yan, Guo, Su Tang, Wang, Jia Yu, Yan, Xu Guang, Farrelly, Margaret, Zhang, Yuan Yuan, Liu, Fen, Yari, Hamed, La, Ting, Lei, Fu Xi, Jin, Lei, Zhang, Xu Dong, Jiang, Chen Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226532/ https://www.ncbi.nlm.nih.gov/pubmed/27391062 http://dx.doi.org/10.18632/oncotarget.10414

Ejemplares similares

Complex Crystal Structure Determination of Hsp90(N)-NVP-AUY922 and In Vitro Anti-NSCLC Activity of NVP-AUY922
por: He, Chun-Xia, et al.
Publicado: (2022)

Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
por: CHENG, WEI, et al.
Publicado: (2015)

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
por: ZITZMANN, KATHRIN, et al.
Publicado: (2013)

NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
por: Lian, Jianpo, et al.
Publicado: (2017)

HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells
por: Bai, Jingchao, et al.
Publicado: (2017)

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

HSP90 Inhibitor, NVP-AUY922, Improves Myelination in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic Mice
por: Chittoor-Vinod, Vinita G., et al.
Publicado: (2019)

The HSP90 Inhibitor, AUY-922, Ameliorates the Development of Nitrogen Mustard-Induced Pulmonary Fibrosis and Lung Dysfunction in Mice
por: Solopov, Pavel, et al.
Publicado: (2020)

Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
por: Kühnel, Annett, et al.
Publicado: (2019)

HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells
por: Tao, Wenjing, et al.
Publicado: (2015)

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
por: Jensen, Michael Rugaard, et al.
Publicado: (2008)

The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage
por: Zaidi, Shane, et al.
Publicado: (2012)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Preferential radiosensitization to glioblastoma cancer stem cell-like cells by a Hsp90 inhibitor, N-vinylpyrrolidone-AUY922
por: Tani, Toshiaki, et al.
Publicado: (2022)

The Co-Chaperone Hch1 Regulates Hsp90 Function Differently than Its Homologue Aha1 and Confers Sensitivity to Yeast to the Hsp90 Inhibitor NVP-AUY922
por: Armstrong, Heather, et al.
Publicado: (2012)

Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line
por: Mohammadian, Mahshid, et al.
Publicado: (2020)

The Role of HSP70 in the Protective Effects of NVP-AUY922 on Multiple Organ Dysfunction Syndrome in Endotoxemic Rats
por: Liu, Pang-Yen, et al.
Publicado: (2021)

Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma
por: ISHIKAWA, CHIE, et al.
Publicado: (2016)

AUY922 induces retinal toxicity through attenuating TRPM1
por: Shen, Che-Hung, et al.
Publicado: (2021)

MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule
por: Grabenbauer, Felix, et al.
Publicado: (2018)

The HSP90 Inhibitor, AUY-922, Protects and Repairs Human Lung Microvascular Endothelial Cells from Hydrochloric Acid-Induced Endothelial Barrier Dysfunction
por: Colunga Biancatelli, Ruben M. L., et al.
Publicado: (2021)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

A Low Membrane Hsp70 Expression in Tumor Cells With Impaired Lactate Metabolism Mediates Radiosensitization by NVP-AUY922
por: Schwab, Melissa, et al.
Publicado: (2022)

NVP-AUY922 alleviates radiation-induced lung injury via inhibition of autophagy-dependent ferroptosis
por: Li, Li, et al.
Publicado: (2022)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia–lymphoma cells
por: Taniguchi, Hiroaki, et al.
Publicado: (2014)

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
por: Kong, Anthony, et al.
Publicado: (2016)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Elucidation of the Molecular Pathways Involved in the Protective Effects of AUY-922 in LPS-Induced Inflammation in Mouse Lungs
por: Akhter, Mohammad S., et al.
Publicado: (2021)

MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2014)

Heat shock protein 90 inhibitor AUY922 attenuates platelet-derived growth factor-BB-induced migration and proliferation of vascular smooth muscle cells
por: Kim, Jisu, et al.
Publicado: (2020)

Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule
por: Djuzenova, Cholpon S., et al.
Publicado: (2016)

Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?()
por: Mayor-López, Leticia, et al.
Publicado: (2014)

Artesunate, as an Hsp90 inhibitor, inhibits the proliferation of Burkitt’s lymphoma cells by inhibiting AKT and ERK
por: Yuan-Ce, Li, et al.
Publicado: (2023)

SPDR-1 HSP90 inhibition overcomes resistant to molecular targeted therapy in BRAF(V600E) mutant glioblastoma
por: Sasame, Jo, et al.
Publicado: (2021)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1/ERK Pathway in Lung Cancer
por: Niu, Mengyuan, et al.
Publicado: (2022)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8h0j7618bqnbmh4kr21jqcluhp